TheEdgeResearch
Home / Stocks / FWPAY

Forward Pharma A/S (FWPAY)

OTC Healthcare Biotechnology
$300.00 ▼ -25.09%
Market Cap
$7.4M
Sector
Healthcare
Industry
Biotechnology
Beta
1.02
52-Wk Range
200.0-882.85626
CEO
Claus Bo Søndergaard Svendsen
Country
DK
Currency
USD

Forward Pharma A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Copenhagen, DK. The stock last traded at $300.00, down 25.09% on the session, giving a market capitalisation of $7.4M. On trailing twelve-month figures it carries a trailing P/E of -3.88, a net margin of 0.0%. Its beta of 1.02 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-3.88
Price / Sales
0.00
Price / Book
0.10
EV / EBITDA
33.47
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
117.44
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
4
IPO date
2014-10-15
Headquarters
Copenhagen, DK
About Forward Pharma A/S

Forward Pharma A/S currently conducts no significant business activities. In its prior operations, the company functioned as a biopharmaceutical firm. It dedicated its efforts to advancing FP187, its exclusive formulation of dimethyl fumarate, designed to address inflammatory and neurological disorders. Forward Pharma A/S was founded in 2005 and maintains its corporate headquarters in Copenhagen, Denmark.

Comparable companies

Forward Pharma A/S is most often compared with the following Healthcare names:

BNOEFCRBKFFLWPFHBCNFIMUNIPCIFPOLXFPSCBFTBPMFTRYPF
More research on FWPAY
FWPAY technical analysis FWPAY TheEdge Score Compare against peers
Open full interactive analysis & DCF →